Obstetrics and Gynecology

Kimberly Leslie, MD

Portrait

Mailing Address

Office: 31140-A PFP
Iowa City, IA 52242
Phone: +1 319 356 1976
Email: kimberly-leslie@uiowa.edu

Education

BS, Psychology, Baylor University, Waco, TX, 1975
BS, Biology and Biochemistry, Texas Christian University, Fort Worth, TX, 1977
MD, Medicine, Southwestern Medical School, University of Texas, Dallas, TX, 1981
Residency, Obstetrics and Gynecology, Parkland Memorial Hospital, Dallas, TX, 1982
Residency, Obstetrics and Gynecology, Georgetown University Affiliated Hospitals, Washington, DC, 1985
Fellowship, Maternal-fetal Medicine, Georgetown University, Washington, DC, 1987

Appointments

Primary: Obstetrics & Gynecology

Center and Program Affiliations

  • Interdisciplinary Graduate Program in Molecular and Cellular Biology

Publications

  • Yang, S, Xiao, X, Meng, X, Leslie, K. A mechanism for synergy with combined mTOR and PI3 kinase inhibitors. PLoS One 6(10):e26343, 2011. [PubMed]
  • Yang, S, Thiel, K, De Geest, K, Leslie, K. Endometrial cancer: reviving progesterone therapy in the molecular age. Discov Med 12(64):205-12, 2011. [PubMed]
  • Meng, X, Brachova, P, Yang, S, Xiong, Z, Zhang, Y, Thiel, K, Leslie, K. Knockdown of MTDH sensitizes endometrial cancer cells to cell death induction by death receptor ligand TRAIL and HDAC inhibitor LBH589 co-treatment. PLoS One 6(6):e20920, 2011. [PubMed]
  • Yang, S, Thiel, K, Leslie, K. Progesterone: the ultimate endometrial tumor suppressor. Trends Endocrinol Metab 22(4):145-52, 2011. [PubMed]
  • Davies, S, Dai, D, Pickett, G, Thiel, K, Korovkina, V, Leslie, K. Effects of bevacizumab in mouse model of endometrial cancer: Defining the molecular basis for resistance. Oncol Rep 25(3):855-62, 2011. [PubMed]
  • Bolnick, J, Albitar, L, Laidler, L L, Abdullah, R, Leslie, K K. Blocking Epidermal Growth Factor Receptor Signaling in HTR-8/SVneo First Trimester Trophoblast Cells Results in Dephosphorylation of PKBα/AKT and Induces Apoptosis. Obstet Gynecol Int 2011:896896, 2011. [PubMed]
  • Singh, M, Darcy, K, Brady, W, Clubwala, R, Weber, Z, Rittenbach, J, Akalin, A, Whitney, C, Zaino, R, Ramirez, N, Leslie, K. Cadherins, catenins and cell cycle regulators: impact on survival in a Gynecologic Oncology Group phase II endometrial cancer trial. Gynecol Oncol 123(2):320-8, 2011. [PubMed]
  • Aghajanian, C, Sill, M, Darcy, K, Greer, B, McMeekin, D, Rose, P, Rotmensch, J, Barnes, M, Hanjani, P, Leslie, K. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. J Clin Oncol 29(16):2259-65, 2011. [PubMed]
  • Schickling, B, Aykin-Burns, N, Leslie, K, Spitz, D, Korovkina, V. An inhibitor of K+ channels modulates human endometrial tumor-initiating cells. Cancer Cell Int 11(1):25, 2011. [PubMed]
  • Santillan, M, Santillan, D, Hamilton, W, Hunter, S, Leslie, K, Rayburn, W. Adaptations in maternal sera of immuno-vasoactive IDO, trail, and IL-4 in response to a high sFLT-1 preeclamptic environment. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY 204(null):S303-S304, JAN 2011.